Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening.

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Oncology

Background:

• Proteasome inhibitors are crucial in cancer therapy.
• Drug resistance to existing proteasome inhibitors (bortezomib, carfilzomib) limits treatment efficacy.
• Novel therapeutic strategies are needed to overcome resistance and improve outcomes.

Purpose of the Study:

• To identify and optimize a novel proteasome inhibitor.
• To evaluate the efficacy of the new compound against solid tumors.
• To assess its effectiveness in the context of drug resistance.

Main Methods:

• Virtual screening of approximately 340,000 small molecules against proteasome active sites.
• In vitro assays for compound validation and optimization.
• In vivo studies to assess efficacy in suppressing solid tumor growth.

Main Results:

• Identification of a potent proteasome inhibitor featuring a pyrazole scaffold.
• The pyrazole-scaffold compound demonstrated excellent metabolic stability.
• Significant suppression of solid tumor growth was observed in vivo.
• The compound's efficacy was unaffected by resistance to bortezomib or carfilzomib.

Conclusions:

• A novel pyrazole-scaffold proteasome inhibitor has been successfully developed.
• This compound shows promising therapeutic potential for solid tumors, including those resistant to current treatments.
• Further development could offer a new treatment option for proteasome inhibitor-resistant cancers.